Home Nav
Nextech Invest Logo

news

News

22.06.2018

Autolus

Autolus announces pricing of initial public offering

21.06.2018

Blueprint Medicines

Blueprint Medicines initiates VOYAGER Phase 3 Clinical trial of avapritinib in patients with advanced gastrointestinal stromal tumors

20.06.2018

Kura Oncology

Kura Oncology appoints chief operating officer, expands clinical development team as company prepares for first registration-directed trial

15.06.2018

Blueprint Medicines

Blueprint Medicines announces updated data from ongoing Phase 1 EXPLORER clinical trial of avapritinib in patients with advanced systemic mastocytosis showing profound and durable clinical activity

13.06.2018

Tracon Pharmaceuticals

Tracon Pharmaceuticals announces presentation of preclinical data from studies of TRC105 in combination with a PD-1 antibody in murine models of colorectal cancer

04.06.2018

Blueprint Medicines

Blueprint Medicines and CStone Pharmaceuticals announce exclusive collaboration and license agreement to develop and commercialize avapritinib, BLU-554 and BLU-667 in Greater China

02.06.2018

Jounce Therapeutics

Jounce Therapeutics presents preliminary efficacy data from ongoing Phase 1/2 ICONIC Trial of JTX-2011 in patients with advanced cancers

30.05.2018

Tracon Pharmaceuticals

Tracon Pharmaceuticals appoints biotech industry veteran Mark Wiggins as chief business officer

22.05.2018

Kura Oncology

Kura Oncology announces screening collaboration with OncoDNA

16.05.2018

Jounce Therapeutics

Jounce Therapeutics to present data from ongoing ICONIC trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

08.05.2018

Kura Oncology

Kura Oncology reports first quarter 2018 financial results and provides corporate update

08.05.2018

Autolus

Autolus files for proposed initial public offering in the United States

02.05.2018

Kura Oncology

Kura Oncology announces new patent for tipifarnib in hematologic malignancies

02.05.2018

Blueprint Medicines

Blueprint Medicines reports first quarter 2018 financial results

02.05.2018

Jounce Therapeutics

Jounce Therapeutics to announce first quarter 2018 financial results and host conference call on Wednesday, May 9, 2018

01.05.2018

Kura Oncology

Kura Oncology to report first quarter 2018 financial results

25.04.2018

Blueprint Medicines

Blueprint Medicines to report first quarter 2018 financial results on Wednesday, May 2, 2018

23.04.2018

Autolus

Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies

17.04.2018

Autolus

Autolus announces presentation of preliminary data showing early signs of clinical activity for a GD2-targeting CAR T cell therapy in a solid tumour setting at the AACR Annual Meeting

15.04.2018

Blueprint Medicines

Blueprint Medicines publication in Cancer Discovery highlights preclinical and clinical proof-of-concept data for highly selective RET inhibitor BLU-667

Newsletter

Keep me updated about investment opportunities in the area of oncology and life sciences.

Register


Latest Newsletters

April 2018October 2017May 2017February 2017

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close

This website uses cookies to provide you with the best possible service. By using our website, you consent to the use of cookies in accordance with our privacy policy. Here you can find out more.